A Case of Sporotrichosis Successfully Treated with Terbinafine.

Asai, Toshiko; Asaya, Masafumi; Tanuma, Hiroyuki; Abe, Michiko

doi:10.2336/nishinihonhifu.56.780

Nishinihon J Dermatol

1994

DOI: 10.2336/nishinihonhifu.56.780

|View full text |Cite

A Case of Sporotrichosis Successfully Treated with Terbinafine.

Toshiko Asai¹,

Masafumi Asaya²,

Hiroyuki Tanuma³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1999

2004

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Therapeutic potential of terbinafine in subcutaneous and systemic mycoses

Hay

1999

Br J Dermatol

View full text Add to dashboard Cite

Mycoses vary widely in severity, and may present as superficial, subcutaneous and/or systemic infection. Effective treatments for most superficial mycoses now exist, but new agents with convenient dosing regimens and a low level of adverse events are still needed to reduce morbidity and mortality from serious subcutaneous and systemic fungal infections. In vitro, terbinafine exhibits a broad spectrum of activity against the pathogenic fungi responsible for deep mycoses. Clinical data, while not abundant, suggest that this in vitro activity of terbinafine is reflected in its in vivo efficacy. The limited data show that terbinafine is a useful first-line treatment in chromoblastomycosis patients and has efficacy in pulmonary aspergillosis. There are also data to suggest that terbinafine may be effective in treating histoplasmosis, Pneumocystis carinii infection, fungal mycetoma, and cutaneous leishmaniasis. Moreover, there is some evidence of terbinafine having synergistic activity with amphotericin B, itraconazole, and fluconazole against clinical isolates of Candida species. Thus, the therapeutic potential of terbinafine extends well beyond its current use in acute and chronic dermatophytoses to include a wide range of subcutaneous and systemic mycoses. Studies are needed to determine the optimum dose in each disease, and whether combination therapy would have advantages in certain circumstances.

show abstract

Therapeutic potential of terbinafine in subcutaneous and systemic mycoses

Hay

1999

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Observation of 21 Sporotrichosis Cases Examined in the Nagasaki Area from 1993 to 2001

Muroi¹,

Katayama²,

Ishikawa³

et al. 2004

Nishinihon J Dermatol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Case of Sporotrichosis Successfully Treated with Terbinafine.

Cited by 2 publications

References 9 publications

Therapeutic potential of terbinafine in subcutaneous and systemic mycoses

Therapeutic potential of terbinafine in subcutaneous and systemic mycoses

Observation of 21 Sporotrichosis Cases Examined in the Nagasaki Area from 1993 to 2001

Contact Info

Product

Resources

About